Trial · NCT02230670

A Study of IDN-6556 in Subjects With Liver Cirrhosis

NCT02230670, Phase 2, Completed, Conatus Pharmaceuticals Inc.; results first posted 2017-07-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of IDN-6556 in Subjects With Liver Cirrhosis. Trials, record NCT02230670. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02230670

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of IDN-6556 in Subjects With Liver Cirrhosis
NCT number: NCT02230670
Status: Completed
Phases: Phase 2
Enrollment: 87 participants, actual
Lead sponsor: Conatus Pharmaceuticals Inc.
Conditions: Liver Cirrhosis, Hepatic Cirrhosis
Interventions: IDN-6556, Placebo
First posted: 2014-09-03
Last updated: 2017-07-05
Results first posted: 2017-07-05

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline at Month 3 in cCK18/M30	3 months	Baseline, Month 3, and change between for cCK18/M30
Primary	Change From Baseline at Month 3 in cCK18/M30	3 months	Data was log-transformed for analysis purposes
Secondary	Change From Baseline to Month 3 in MELD Score	3 Months	The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing the severity of chronic liver disease and uses the subject's values for total bilirubin, serum creatinine, and the international normalized ratio (INR) for prothrombin time to predict survival. MELD is calculated according to the following formula: MELD = 3.78×ln\[serum bilirubin (mg/dL)\] + 11.2×ln\[INR\] + 9.57×ln\[serum creatinine (mg/dL)\] + 6.43 MELD scores are reported as whole numbers, so the result of the equation above is rounded. Notes: If the patient has been dialyzed twice within the last 7 days, then the value for serum creatinine used should be 4.0. Any value less than one is given a value of 1 (i.e. if bilirubin is 0.8, a value of 1.0 is used) to prevent the occurrence of scores below 0 (the natural logarithm of 1 is 0, and any value below 1 would yield a negative result). The higher the MELD score the more severe the disease state.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline at Month 3 in cCK18/M30	3 months	FAS	U/L	MEDIAN
PRIMARY	Change From Baseline at Month 3 in cCK18/M30	3 months	Full analysis set	U/L	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline to Month 3 in MELD Score	3 Months	FAS	units on a scale	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change From Baseline at Month 3 in cCK18/M30	IDN-6556	Baseline	293.5	Full Range 66 to 1857	U/L
Change From Baseline at Month 3 in cCK18/M30	Placebo	Baseline	257.5	Full Range 104 to 6994	U/L
Change From Baseline at Month 3 in cCK18/M30	IDN-6556	Month 3	288.5	Full Range 39 to 1583	U/L
Change From Baseline at Month 3 in cCK18/M30	Placebo	Month 3	285.0	Full Range 115 to 19710	U/L
Change From Baseline at Month 3 in cCK18/M30	IDN-6556	Log-transformed Values	-0.049	Standard Error 0.057	U/L
Change From Baseline at Month 3 in cCK18/M30	Placebo	Log-transformed Values	0.090	Standard Error 0.058	U/L
Change From Baseline at Month 3 in cCK18/M30	IDN-6556	Percent (%) Relative Change	-4.6	Standard Error 5.9	U/L
Change From Baseline at Month 3 in cCK18/M30	Placebo	Percent (%) Relative Change	9.3	Standard Error 5.9	U/L
Change From Baseline to Month 3 in MELD Score	IDN-6556		-0.10	Standard Error 0.234	units on a scale
Change From Baseline to Month 3 in MELD Score	Placebo		0.15	Standard Error 0.239	units on a scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	IDN-6556	44
Overall Study	STARTED	Placebo	42
Overall Study	COMPLETED	IDN-6556	40
Overall Study	COMPLETED	Placebo	34
Overall Study	NOT COMPLETED	IDN-6556	4
Overall Study	NOT COMPLETED	Placebo	8

Source ClinicalTrials.gov

Adverse events58

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	abdominal pain	Gastrointestinal disorders	IDN-6556 (Baseline-Month 3)	3	44	3
other	abdominal pain	Gastrointestinal disorders	Placebo (Baseline-Month 3)	3	42	3
other	arthralgia	General disorders	IDN-6556 (Baseline-Month 3)	3	44	3
other	arthralgia	General disorders	Placebo (Baseline-Month 3)	0	42	0
other	ascites	Gastrointestinal disorders	IDN-6556 (Baseline-Month 3)	1	44	2
other	ascites	Gastrointestinal disorders	Placebo (Baseline-Month 3)	3	42	3
other	fatigue	Metabolism and nutrition disorders	IDN-6556 (Baseline-Month 3)	4	44	4
other	fatigue	Metabolism and nutrition disorders	Placebo (Baseline-Month 3)	6	42	7
other	headache	Nervous system disorders	IDN-6556 (Baseline-Month 3)	7	44	8
other	headache	Nervous system disorders	Placebo (Baseline-Month 3)	3	42	4

1 to 10 of 58Source ClinicalTrials.gov

See all 58 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	IDN-6556 (Baseline-Month 3)	0	44
Total, all-cause mortality	Placebo (Baseline-Month 3)	0	42
Total, other adverse events	IDN-6556 (Baseline-Month 3)	34	44
Total, other adverse events	Placebo (Baseline-Month 3)	30	42
Total, serious adverse events	IDN-6556 (Baseline-Month 3)	6	44
Total, serious adverse events	Placebo (Baseline-Month 3)	5	42

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
29913280	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
IDN-6556 (Baseline-Month 3) vs Placebo (Baseline-Month 3): deaths from any cause	Trial comparisons
IDN-6556 (Baseline-Month 3) vs Placebo (Baseline-Month 3): serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02230670

GET https://conductscience.org/api/trials/v1/NCT02230670/events?page=2

API reference For AI assistants